CDC7 and diffuse large B-cell lymphoma: For example, BRD4 (targeted by bromodomain inhibitors), CDC7 (TAK-931), HDAC3 (vorinostat), PRMT5 (GSK-3326595), NEDD8 (MLN4924), and ATR (VX-970), as well as XPO1 (selinexor), which is approved for advanced diffuse large B cell lymphoma and multiple myeloma [46], are all pan-dependencies using CRISPR knockout and selective dependencies using RNAi suppression.